Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices 6893 

(HHS Reference No. E–003–2014–0–US– 

07); 

4. International Patent Application 

No. PCT/US2015/011433, filed 14 

January 2015 (HHS Reference No. E– 

003–2014–0–PCT–02); 

5. Australia Patent No. 2015206515, 

issued 26 March 2020 (HHS Reference 

No. E–003–2014–0–AU–03); 

6. Canada Patent Application No. 

2931005, filed 14 January 2015 (HHS 

Reference No. E–003–2014–0–CA–04); 

7. European Patent No. 3 094 350 B1, 

issued 04 March 2020 (HHS Reference 

No. E–003–2014–0–EP–05) and all of its 

national validations; 

8. European Patent Application No. 

19219282.1, filed 14 January 2015 (HHS 

Reference No. E–003–2014–0–EP–11); 

and 

9. any and all other U.S. and ex-U.S. 

patents and patent applications 

claiming priority to any one of the 

foregoing, now or in the future. 

The patent and patent application 

rights in these inventions have been 

assigned and/or exclusively licensed to 

the government of the United States of 

America. 

The prospective exclusive license 

territory may be worldwide and the 

fields of use may be limited to the 

following: The development, 

manufacture, distribution, sale and use 

of one or more fusion proteins for the 

treatment of humans with short stature 

associated with one or more genetic 

conditions. 

These technologies disclose, e.g., 

monoclonal antibodies and antibody 

fragments that specifically bind to 

matrilin-3, conjugates including these 

molecules, and nucleic acid molecules 

encoding the antibodies, antigen 

binding fragments and conjugates. Also 

disclosed are compositions including 

the disclosed antibodies, antigen 

binding fragments, conjugates, and 

nucleic acid molecules. Methods of 

treating or inhibiting a cartilage disorder 

in a subject, as well as methods of 

increasing chondrogenesis in cartilage 

tissue are further provided. The 

methods can be used, for example, for 

treating or inhibiting a growth plate 

disorder in a subject, such as a skeletal 

dysplasia or short stature. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR 404. The 

prospective exclusive license will be 

royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 11, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–01488 Filed 1–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel: R21 Mechanism for TimeSensitive Research Opportunities in 

Environmental Health Sciences. 

Date: February 19, 2021. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Environmental 

Health Sciences, Keystone Building, 530 

Davis Drive, Durham, NC 27709 (Virtual 

Meeting). 

Contact Person: Laura A. Thomas, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research and 

Training, National Institute of Environmental 

Health Science, Research Triangle Park, NC 

27709, 984–287–3328, laura.thomas@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: January 15, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–01443 Filed 1–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST–2 Conflict SEP 

Additional Applications. 

Date: February 18, 2021. 

Time: 9:00 a.m. to 10:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Delany Torres, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS, Neuroscience Center Building (NSC), 

6001 Executive Blvd., Suite 3208, Rockville, 

MD 20852, delany.torressalazar@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST–1 Additional 

Applications. 

Date: March 2, 2021. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


jbell on DSKJLSW7X2PROD with NOTICES